Streetbeat News

Products Services

ENLV

Enlivex has received authorization from the Danish Medicines Agency for a Phase I/II trial to evaluate Allocetra in treating knee osteoarthritis. This marks a significant step forward in the development of Allocetra, potentially opening new treatment avenues for patients with this condition.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:57 am

CGEM

Cullinan Therapeutics shares are trading higher following the company's announcement of its plans to expand into autoimmune diseases.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:50 am

HMC

Honda Motor Co Ltd (NYSE:HMC) announced plans to launch six Ye Series EV models in China by 2027, including the Ye P7 and Ye S7, and a concept model, Ye GT CONCEPT. These models, featuring a new dedicated EV platform and Honda's electrification technologies, aim to expand Honda's EV lineup in China, where the company is already offering the e:N Series. The Ye P7 and Ye S7 will come in two variants and are set to go on sale by the end of 2024 and 2025, respectively. HMC shares dropped 1.42% in premarket trading.

Portfolio Pulse from Shivani Kumaresan

April 16, 2024 | 11:48 am

AMD

FTXL

INTC

NVDA

SOXQ

Intel and Nvidia are adapting their AI chip strategies for the Chinese market in response to U.S. sanctions by launching China-specific products with reduced capabilities. Intel plans to release two AI chips, HL-328 and HL-388, while Nvidia is developing three China-specific chips. These moves come as both companies face challenges in China due to the country's push to remove foreign technology from its telecom networks by 2027. Intel's stock has seen a 13% increase over the last 12 months, and its performance can also impact related ETFs like FTXL and SOXQ.

Portfolio Pulse from Anusuya Lahiri

April 16, 2024 | 11:47 am

BRTX

BioRestorative Therapies has received FDA clearance for an amendment to the Phase 2 clinical study protocol of BRTX-100, a significant step forward in its development process.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:46 am

CGEM

Cullinan Therapeutics announces a strategic shift to focus on the development of CLN-978 for autoimmune diseases, specifically targeting systemic lupus erythematosus as the first indication. The company has discontinued enrollment in its B-NHL study to concentrate on autoimmune indications. This decision follows clinical observations from the CLN-978 B-NHL study, which demonstrated rapid, deep, and sustained B cell depletion and clinical activity. Additionally, the company has undergone a corporate name change to Cullinan Therapeutics to reflect its strategic expansion into autoimmune diseases. A virtual investor event is scheduled for April 16 at 8:00 am ET to discuss these developments.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:44 am

LXEO

Lexeo Therapeutics' stock price increased following the announcement that its gene therapy candidate LX2006, aimed at treating Friedreich's ataxia cardiomyopathy, received FDA Fast Track designation.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:37 am

AADR

E

IDGT

Eni S.p.A. (NYSE:E) shares are trading lower today due to plans to sell minority stakes in its biofuel and bio-plastic units by year-end, aiming to raise EUR1.3 billion. Preliminary discussions are underway with potential partners for up to 10% of the biofuel unit, Enilive, which could be valued at over EUR10 billion, including debt. Options for Enilive include an IPO or a spin-off. Eni is also negotiating the sale of up to 30% of its bio-plastic business, Novamont, potentially valued at around EUR1 billion. These moves are part of Eni's strategy to fund greener businesses without impacting its oil and gas operations.

Portfolio Pulse from Lekha Gupta

April 16, 2024 | 11:36 am

PRZO

ParaZero announced its entry into the Counter Unmanned Aircraft System market, signaling a strategic expansion of its business operations.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:35 am

CYBN

Cybin announced the grant of an additional US patent supporting its CYB003 program for Major Depressive Disorder, potentially strengthening its intellectual property and therapeutic offering.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:35 am